Abstract
Introduction: Drug- induced liver injury due to chemotherapy is an important cause of morbidity in cancer patients, although its clinical manifestations are poorly understood. It is known that liver metabolism has some phenotypical differences.Aim: To assess if we have any different profile of liver toxicity in cancer patients upon receiving first dose receiving Anthracyclines at King Abdulaziz University Hospital (KAUH). Patients and Method: This study was performed on 50 cancer patients who received anthracyclines at the department of Day Care Unit (DCU), KAUH, Jeddah between 2012 to 2017. The participants were selected based on predetermined inclusion criteria. The inclusion criteria were receiving anthracyclines chemotherapy (first dose) and the availability of patients' data before and after administration of anthracyclines. The sample collection procedures followed were in accordance with the local ethical guidelines. Patients date that obtained were; (age, gender, disease, therapeutic agent, administration date, results of liver function tests aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin (T.Bil) before and after administration of anthracyclines). Results: Our results conveyed that the ALT, GGT, and T.Bil were the only parameters that provided statistical significance difference. AST results provided a borderline significance difference. ALP, TP and ALB results showed no significant difference. Conclusion: we failed to reject the null hypothesis and conclude that the liver function tests (ALT, AST, ALP, and T.Bil) are not increased after receiving the first dose of anthracyclines in cancer patients.